Who is the new Vice President of Marketing at Compugen?

Compugen named Kara Rudy Vice President of Marketing, announced January 22, 2024.

Which similar companies made leadership changes around the same time?

Corcept (January 29, 2024), Neumora (January 22, 2024), Mirai Medical (January 23, 2024) and Rezolute (January 24, 2024) also announced leadership changes within 45 days of Compugen.

Compugen Welcomes Kara Rudy as Vice President, Marketing

PUBLIC · CGENJan 22, 2024

Position

Vice President of Marketing

Company

Compugen

Kara Rudy

krudy@compugen.com

Tel AvivOtherBiotechnologyHealth CareMedicalTherapeuticsBiotechnology Research

Description

Compugen Inc. is pleased to announce the appointment of Kara Rudy as its new Vice President, Marketing, effective January 1.

Quick answer

Compugen Welcomes Kara Rudy as Vice President, Marketing (January 22, 2024). Compugen is based in Tel Aviv, Tel Aviv District, Israel.

Who is the new Vice President of Marketing at Compugen?: Compugen named Kara Rudy Vice President of Marketing, announced January 22, 2024.
What did Compugen announce on January 22, 2024?: Compugen Inc. is pleased to announce the appointment of Kara Rudy as its new Vice President, Marketing, effective January 1.
What does Compugen do?: Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for...
Where is Compugen based?: Compugen is based in Tel Aviv, Tel Aviv District, Israel.
Which similar companies made leadership changes around the same time?: Corcept (January 29, 2024), Neumora (January 22, 2024), Mirai Medical (January 23, 2024) and Rezolute (January 24, 2024) also announced leadership changes within 45 days of Compugen.

Source: Fundz verified event record.

Other recent leadership changes in Medical and Therapeutics

Executive moves at companies in the same sectors within 45 days, from Fundz verified event records.

Corcept Appoints Roberto Vieira as President, Oncology (January 29, 2024)
Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial Officer (January 22, 2024)
Mirai Medical Welcomes Former Boston Scientific Executive, David A. Pierce, as Non-Executive Director (January 23, 2024)
Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer (January 24, 2024)
TScan Therapeutics Appoints Seasoned Industry Executive Jason A. Amello as Chief Financial Officer (January 29, 2024)
Adverum Biotechnologies Appoints Romuald Corbau, Ph.D. as Chief Scientific Officer (January 29, 2024)

Who to call at Compugen, and when

A new leader at Compugen brings new priorities and often new vendors. The first weeks are when they listen.

An alert the day Compugen raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Compugen, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Compugen. With Fundz connected, it knows.

Watch Fundz in

See plan options

Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Compugen

Location

26 HAROKMIM STREET

Tel Aviv, Tel Aviv District, Israel

About

Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has developed two proprietary product candidates: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Compugen also has a clinical stage partnered program, rilvegostomig (previously AZD2936), a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen’s clinical stage anti-TIGIT antibody, COM902, in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. In addition, the Company’s therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, of which the most advanced program, COM503, is in IND enabling studies is licenced to Gilead. COM503 is a potential first-in-class, high affinity antibody which blocks the interaction between IL-18 binding protein and IL-18, thereby freeing natural IL-18 in the tumor microenvironment to inhibit cancer growth. Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen’s shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Compugen changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Book a demo Explore plans